N-butylbenzamide;hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-butylbenzamide;hydrochloride
• 化学式: C11H16ClNO
• 分子量: 213.7
• InChiKey: UJAWLCKJJDZPTM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.64
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.1
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10603292B2

  公开（公告）日：2020-03-31

  The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.

  本发明涉及包含(E)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-N-叔丁基苯甲酰胺的药物组合物，其化学结构如下 或其药学上可接受的盐作为活性药物成分的药物组合物，特别是包括(E)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-N-叔丁基苯甲酰胺盐酸盐的药物组合物、药物剂型、其制备、使用和治疗方法。
• PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL DOSAGE FORM COMPRISING (E)-4-(2-(AMINOMETHYL)-3-FLUOROALLYLOXY)-N-TERT-BUTYLBENZAMIDE, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3630084A1

  公开（公告）日：2020-04-08
• US8957068B2
  申请人：——

  公开号：US8957068B2

  公开（公告）日：2015-02-17
• [EN] PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL DOSAGE FORM COMPRISING (E)-4-(2-(AMINOMETHYL)-3-FLUOROALLYLOXY)-N-TERT-BUTYLBENZAMIDE, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF<br/>[FR] COMPOSITION PHARMACEUTIQUE ET FORME PHARMACEUTIQUE COMPRENANT DU (E)-4-(2-(AMINOMÉTHYL)-3-FLUOROALLYLOXY)-N-TERT-BUTYLBENZAMIDE, LEUR PROCÉDÉ DE PRÉPARATION, MÉTHODES ET UTILISATIONS EN THÉRAPIE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018219982A1

  公开（公告）日：2018-12-06

  The present invention relates to pharmaceutical compositions comprising (E)-4-(2- (aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having chemical structure (I) or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.